It is well known that cases with multiple myeloma reveal various clinical manifestations such as pancytopenia, hyperproteinemia, renal dysfunction, bone lesions, hypercalcemia and immunodeficiency. Recently, a few more clinical features associated with myeloma, such as salivary type hyperamylasemia and elevated serum C-reactive protein (CRP) concentration, have been reported. The elevation of CRP is thought to be related to interleukin-6 (IL-6) production by myeloma cells, because of identification of IL-6 as an autocrine and/or paracrine growth factor for myeloma cells. More recently, there have been several reports of cases with myeloma associated with hyperammonemia. This hyperammonemia is not considered to be due to liver dysfunction, because in most of these cases tests revealed normal hepatic function, and some cases showed different patterns of serum amino acid distribution than that associated with hepatic failure. However, there have been no apparent observations of ammonia production by myeloma cells. In this study, we used six human myeloma cell lines including KMS-18, which was recently established from a myeloma case associated with hyperammonemia. These lines were treated with MRA (mycoplasma removal agent) to observe ammonia production in vitro. They produced and released significantly higher levels of ammonia into culture medium than non-myeloma hematological cell lines or the HepG2 human hepatic carcinoma cell line. Although attempts to analyze the relative expression levels of the enzymes related to ammonia biosynthesis using the reverse transcriptase-polymerase chain reaction assay failed to detect any differences between these myeloma lines and other cell lines, in vitro excess ammonia production by the myeloma cells was confirmed and the relevance to clinical manifestations is discussed.
Introduction
Multiple myeloma remains an uncurable hematological malignancy characterized by various clinical manifestations such as pancytopenia, hyperproteinemia, renal dysfunction, bone lesions and immunodeficiency. [1] [2] [3] [4] [5] [6] Recently, a few new clinical features associated with myeloma, such as salivary type hyperamylasemia [7] [8] [9] [10] [11] [12] [13] and elevation of the serum Creactive protein (CRP) concentration [14] [15] [16] and oncostatin M, 17 have been reported. Elevation of CRP is thought to be related to interleukin-6 (IL-6) production by myeloma cells, because of the identification of IL-6 as an autocrine and/or paracrine growth factor for myeloma cells. [18] [19] [20] Clinical analyses have also been indicated serum CRP as one of the prognostic factors in myeloma cases.
atic function was found to be normal in most of them, and different patterns of serum amino acid distribution than that in hepatic failure were noted in some of them. 23 In addition, hyperammonemia in myeloma cases is sometimes accompanied by high cardiac output syndrome. 21, 22 However, there has been no observation of ammonia production by myeloma cells. Although one cell line, KHM-4, was reported to produce ammonia in vitro, 25 it has been clarified that ornithine transcarmanylase derived from infected mycoplasma in this cell line played a major role in the production of ammonia in culture. 31 In the only other report concerning ammonia production by a myeloma cell line, RPMI8226, 29 there was no description of mycoplasma status and ammonia production was not measured according to proliferating cell numbers. Therefore, there has been no apparent observation of ammonia production by myeloma cells in vitro so far.
Enzymes such as carbamyl phosphate synthetase I (CPS), ornithine transcarbamylase (OTC), argininosuccinate synthetase (AS), argininosuccinate lyase (AL), and arginase (AR) function in the urea cycle to synthesize ammonia in vitro. [32] [33] [34] An inherited deficiency of the activity of these enzymes or mutations of genes cause hyperammonemia clinically. [35] [36] [37] [38] [39] [40] [41] In addition, glutamate dehydrogenase (GDH) and glutaminase (GL) bring ammonia into the urea cycle from certain amino acids. 32, [42] [43] [44] [45] as schematically shown in Figure 1 . Therefore, altered activities or expression levels of these enzymes may be involved in myeloma cases with hyperammonemia.
In 1996, we established a human myeloma cell line, KMS-18, derived from a case with myeloma complicated by hyperammonemia that showed no hepatic dysfunction clinically. 46 In the present study, we used five human myeloma cell lines including KMS-18, established at Kawasaki Medical School, [47] [48] [49] and one of well characterized myeloma cell line, U266, 50 treated with mycoplasma removal agent (MRA) 51, 52 to observe ammonia production in vitro. These cell lines produce and release significantly higher amounts of ammonia into culture medium (13.65 ± 5.84 mol/l/10 × 10 3 proliferating cells) than non-myeloma hematological cell lines, or the HepG2 human hepatic carcinoma cell line (4.16 ± 1.90 mol/l/10 × 10 3 proliferating cells). Although attempts to analyze relative expression levels of the enzymes which are related to ammonia biosynthesis using the reverse transcriptase-polymerase chain reaction (RT-PCR) assay failed to detect any differences between myeloma cell lines and the other lines examined, in vitro excess ammonia production of myeloma cells was confirmed and the relevance to clinical manifestations is discussed.
Materials and methods

Cell lines used in this study
Six human myeloma cell lines, KMM-1, KMS-11, KMS-12-PE, KMS-12-BM, KMS-18 (these lines were established at Kawasaki Medical School) and U266, were used in this study.
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Figure 1
Schematic representation of the biochemical urea cycle and enzymes related to ammonia metabolism.
Table 1
Ammonia production (mol/l) and release into the culture medium depending on single amino acid supplementation using SelectAmin Kit, in myeloma cell lines, non-myeloma hematological cell lines and the HepG2 cell line
Single amino acid
Ammonia concentration (mol/l) in culture medium from each cell line supplemented to RPMI1640 KMM-1 KMS-11 KMS-12-PE KMS- 12-BM  KMS-18  KMS-15  HL-60  Raji  Hep G2   L-arginine   177  155  155  148  136  135  131  130  467   L-asparagine   200  199  190  184  168  182  173  170  388  L-aspartic acid  174  157  150  138  145  141  133  133  275   L-cystine   161  160  164  151  140  148  168  155  331  L-gultamic acid  172  153  143  147  141  134  134  133  329   L-glutamine   567  560  535  507  561  546  521  470  554  Glycine  163  153  148  148  159  136  131  135 Unfortunately, we have no information about hyperammonemia in the cases from which these lines were derived except for KMS-18, which was recently established from a case with hyperammonemia. 46 Ammonia production and release into culture medium and the relative expression levels of enzyme genes related to the biosynthesis of ammonia of those five myeloma cell lines was compared with that of 11 non-myeloma hematological cell lines and HepG2, a human hepatocarcinoma cell line. The non-myeloma cell lines were KMS-15 (an Epstein-Barr virus transformed human lymphoblastoid cell line established in our department), SU-DHL-4, SU-DHL-5, and SU-DHL-6 (derived from transformed follicular lymphomas), Raji (Burkitt's lymphoma), SU-DHL-1 (an anaplastic large cell lymphoma), CEM and Molt4 (T cell acute leukemias), HL-60 (promyelocytic leukemia), U937 (histiocytic leukemia), and K562 (chronic myelogenous leukemia). All cell lines were cultured with RPMI1640 plus 10% fetal bovine serum (FBS) at 37°C in a humidified atmosphere with 5% CO 2 . One half to one tenth of the medium in each dish, depending on the growth characteristics of each cell line, was replaced with fresh medium, twice a week.
All cell lines were treated with MRA 51, 52 (ICN Phamaceuticals, Costa Mesa, CA, USA), according to the manufacturer's instructions to avoid perturbation of ammonia production caused by infected mycoplasma. After treatment with MRA, mycoplasma was tested by the Hoechst 33258 staining method 53 and/or the PCR method with the Mycoplasma PCR Primer Set (Strategene Cloning Systems, La Jolla, CA, USA) using 1 g of extracted DNAs from lines according to the manufacturer's instruction provided with the primer set. Therefore, all cell lines examined were confirmed negative for mycoplasma infection (data not shown).
In addition, peripheral blood mononuclear cells from a healthy volunteer were used for the relative gene expression study described below.
Effect of single amino acid supplementation to RPMI1640 culture medium on ammonia production in the cell lines studied Initially, we examined ammonia production in culture medium depending on single amino acid supplementation using the Select-Amin Kit (GIBCO BRL Life Technologies, Gaithersburg, MD, USA) in five myeloma cell lines established at Kawasaki Medical School, and KMS-15, Raji, HL60, and HepG2 cell lines. Cells were seeded 100 × 10 3 in 35-mm culture dishes with 2 ml of RPMI 1640 medium supplemented with a single amino acid, as shown in Table 1 . Culture media were harvested by centrifugation after 4 days cultivation and immediately frozen until measurement of ammonia. Ammonia concentrations in the media were measured using EKTACHEM 700 N (Johnson and Johnson Clinical Diagnostics, Rochester, NY, USA) immediately after thawing of the samples.
Ammonia production and release into culture medium
Because results using the Select-Amin Kit showed high ammonia production with L-glutamine supplementation, the standard RPMI1640 medium (supplemented with only L-glutamine as an amino acid) was used to compare ammonia production among the cell lines examined. Cells were seeded 100 to 200 × 10 3 in 35-mm culture dishes with 2 ml RPMI 1640 medium on day 0. On days 1 and 4, cells were counted and culture media were harvested. The production of ammonia was calculated as the elevation of the ammonia concentration from days 1 to 4 divided by increasing cell numbers from days 1 to 4 (revealed as mol/l/proliferating cell numbers, 10 × 10 3 cells).
Total RNA extraction and first-strand cDNA synthesis RT-PCR and measurement of relative expression levels of the genes of the enzymes related to ammonia biosynthesis
The primer sets for the ␤-actin, GDH, GL, CPS, OTC, AS, AL and AR genes were as follows:
primer set for ␤-actin F; 5′-TGACGGGGTCACCCACACTGTGCC CATCTA-3′ R; 5′-CTAGAAGCATTTGCGGTGGACGAT GGAGGG-3′ primer set for GDH F; 5′-ACAATGAAGCTGGTGTGACC-3′ R; 5′-AAGACTGCACAGCCAGATGG-3′ primer set for GL F; 5′-GAGGTCACTTGTGAATCAGGC-3′ R; 5′-GCCAGAGAAGTCATACATGCC-3′ primer set for CPS F; 5′-TCTAGTATCCGCACACTGCG-3′ R; 5′-CTGAGAAGATGGAGCGATCC-3′ primer set for OTC F; 5′-TGGCAGATGCAGTATTGGCT-3′ R; 5′-TGGAGTGCAGGATATTGTTCC-3′ primer set for AS F; 5′-AAGGCTATGACGTCATTGCC-3′ R; 5′-TAGCGGTCCTCATACAGTGC-3′ primer set for AL F; 5′-ATGAGGACATCCACACAGCC-3′ R; 5′-CCACCATGGTCCTAATGAGC-3′ primer set for AR F;5′-GAAGTGTCAGAGCATGAGCG-3′ R; 5′-TACTTCTTGACTTGTGCCACC-3′
All of the oligonucleotide primers were synthesized by the solid phase triester method. . The final extension time was 7 min. The RT-PCR product from one of the enzyme genes related to ammonia biosynthesis was electrophoresed on 1.2% agarose gel with the RT-PCR product of the ␤-actin gene from the same cell line, and then was stained with ethidium bromide. A gel image was obtained using the FAS-II UV-image analyzer, and the densities of the products were quantitated using the Quantity One version 2.5 (PDI, Huntington Station, NY, USA). The relative expression levels were calculated as the density of the product of the enzyme divided by that of ␤-actin from the same line.
Figure 2
In vitro ammonia production and release into culture medium by six human myeloma cell lines (KMM-1 to U266), 11 non-myeloma hematological cell lines (KMS-15 to K562), and the HepG2 human hepatocellular carcinoma cell line. Cells were seeded 100 to 200 × 10 3 in 35-mm culture dishes with 2 ml RPMI1640 (supplemented with L-glutamine) medium on day 0. On days 1 and 4, cells were counted and culture media were harvested. The production of ammonia was calculated as elevation of ammonia concentration from days 1 to day 4 divided by increasing cell numbers from days 1 to 4 (revealed as mol/l/proliferating cell numbers, 10 × 10 3 cells). The results were obtained by triplicate independent experiments. The average of non-myeloma lines includes the results for the HepG2 and non-myeloma hematological lines. Statistical significance was calculated using Fischer's PLSD test.
Statistical analysis
Statistical significance was calculated using Fisher's PLSD test.
Results
Effect of single amino acid supplementation to RPMI1640 culture medium on ammonia production in the cell lines studied
As shown in Table 1 , all cell lines including five human myeloma cell lines and three non-myeloma cell lines and the HepG2 human hepatic carcinoma cell line showed the highest ammonia production and release into culture medium when the RPMI1640 medium was supplemented with L-glutamine. It may be noteworthy that the HepG2 line demonstrated higher ammonia production than other hematological cell lines including the myeloma lines when amino acids other than L-glutamine were added to the medium separately. This difference may be related to the original organs from which the lines were derived. Even though the HepG2 cells were a carcinoma line, the line was derived from hepatic cells, and the enzyme activities related to ammonia metabolism are considered to be more active in the liver than in the hematopoietic organs.
Based on the above results, we employed L-glutamine supplementation for the comparison assay of ammonia production.
Ammonia production and release into culture medium and comparison among the cell lines examined Ammonia production and release into culture medium was calculated as mol/l/10 × 10 3 proliferating cells during 3 days cultivation based on the results of cell proliferation and ammonia concentration in each cell line as shown in Figure  2 and In addition, the HepG2 cell line showed ammonia production of 4.09 ± 0.52 mol/l/10 × 10 3 proliferating cells. The average ammonia production in the non-myeloma cell lines including the HepG2 cell line was 4.16 ± 1.90, which was significantly less statistically than that of the myeloma cell lines (P Ͻ 0.005). Table 2 Results of cell proliferation and ammonia concentration in culture supernatant in each cell line studied The experiments were performed at least three times.
These results indicate that human myeloma cell lines produced and released more ammonia into culture medium in vitro than the non-myeloma cell lines. This phenomenon may represent the clinical manifestation of hyperammonemia in myeloma cases without hepatic dysfunction.
RT-PCR for genes of enzymes related to ammonia biosynthesis
To elucidate the mechanisms of ammonia production in human myeloma cells, we analyzed the relative expression levels for the genes of enzymes related to its biosynthesis. The GDH, GL, CPS, OTC, AS, AL and AR genes were examined using the RT-PCR method and the amounts of products were compared with that of the ␤-actin gene product. To assess the expression levels for each enzyme gene semiquantitatively, 27 cycles of the RT-PCR for the ␤-actin gene were performed using cDNA equivalent to 10 ng of initial total RNA to obtain logarithmic amplification. In addition, the expression levels for each gene were measured as the amount of enzyme gene product divided by the ␤-actin gene product, which was run on to the same gel, and were derived from the same cell line cDNA.
The gels for each enzyme gene and the ␤-actin gene are shown in Figure 3 and the relative expression levels of each enzyme-gene are summarized in Table 3 . Most of the enzyme genes examined in this study, with the exception of CPS and AR, were amplified from all of the cell lines studied. KMS-12-PE and KMS-12-BM did not show any products of the CPS gene. AR gene products were only seen in the HepG2 cell line.
In addition to sole expression of the AR gene, the HepG2 cell line demonstrated higher expression enzyme genes with the exception of the OTC gene than the ␤-actin gene (the ratios were more than 1.0), as shown in Table 3 . This may be related to the organs from which the lines originated in the case of higher ammonia production in most of the single Table 3 Comparison of relative expression levels for enzyme genes related to ammonia production among myeloma cell lines, non-myeloma hematological cell lines, and the hepatocellular carcinoma cell line, or PBMC amino acid supplementation in the HepG2 cells described above. However, relative expression levels of enzyme genes in the hematological lines and PBMC varied from enzyme to enzyme, and from line to line. Because the ammonia production in the myeloma cell lines was significantly higher than in the others cell lines, the minimum production in the myeloma lines (7.36 ± 0.76 in KMM-1 line) being higher than the highest production in the nonmyeloma cell line (5.30 ± 0.38 in SU-DHL-1 line), the average relative expression levels in the five myeloma cell lines were RT-PCR products for the genes of the enzymes related to ammonia biosynthesis are described in Figure 1 . RT-PCRs were performed as described in Materials and methods. The cells examined were those of five human myeloma cell lines and six non-myeloma hematological cell lines, HepG2, and peripheral blood mononuclear cells from a healthy volunteer. PBMC, peripheral blood mononuclear cells; GDH, glutamate dehydrogenase; GL, glutaminase; CPS, carbamyl phosphate synthetase; OCT, ornithine transcarbamylase; AS, argininosuccinate synthetase; AL, argininosuccinate lyase; AR, arginase. All products were run onto 1.2% agarose gel and were stained with ethidium bromide. The gel images are shown in inverted presentation. compared with those of the non-myeloma hematological cell lines, with the exception of AR gene expression. However, as shown in Figure 4 , there were no significant differences among the myeloma lines and non-myeloma lines regarding the relative expression levels of the GDH GL, CPS, OTC, AS or AL genes.
These analyses of the gene expression of the enzyme genes related to ammonia metabolism suggest that in vitro overproduction of ammonia in human myeloma cell lines is not dependent on the RNA level expression of the enzymes related to its biosynthesis. Although we have not examined the biochemical activities of each enzyme studied here as yet, it is usually considered that approximately 10-20% of the biochemical activities of enzymes may be enough to act on physiologically. 32, 54 Therefore, the enzyme activities examined in the present study may not be significantly involved because with the exception of AR, they were all certainly expressed at the mRNA level without significant differences between the myeloma (high ammonia) lines and the nonmyeloma (low ammonia) lines.
Discussion
Hyperammonemia is a clinical manifestation of various conditions such as liver failure. 55, 56 Reye's syndrome 57, 58 and congenital metabolic disorders. [32] [33] [34] In most such cases with hyperammonemia, the biochemical metabolism of ammonia is impaired in various ways and the blood concentration of ammonia is elevated to toxic levels. In addition, hyperammonemia has also been reported to be associated with urinary tract infections, 59 ,60 valproic acid treatment, 61, 62 portacaval shunts in cases with gastric cancer 63 and high-dose cytoreductive chemotherapies for cases with hematological malignancies. 64 Recently, there have been several reports of cases with myeloma associated with hyperammonemia, [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] most of whom have been Japanese. This hyperammonemia was not considered to be due to liver dysfunction, because most of these cases had normal hepatic function and some showed different patterns of serum amino acid distributions than that of liver failure. 23, 28, 29 However, there has been no apparent observation of ammonia production by myeloma cells. Although one cell line, KHM-4, was reported to have produced ammonia in vitro, 25 it was clarified that ornithine transcarmanylase derived from infected mycoplasma in this cell line was the major factor that produced ammonia in culture.
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Figure 4
Comparison of relative expression levels for the genes of the enzymes related to ammonia biosynthesis and the ␤-actin gene. The relative expression levels were calculated as the density of the product for enzyme genes divided by that of the ␤-actin gene from the same cell line run onto the same gel. MM, multiple myeloma cell lines; Non-MM, non-myeloma hematological cell lines; PBMC, peripheral blood mononuclear cells from healthy volunteer. MM shows the average relative expression level of each gene of five myeloma lines, while Non-MM shows the average of 11 non-myeloma cell lines, excluding HepG2 line.
In another report concerning ammonia production by a myeloma cell line in which RPMI8226 was used, 29 no description of mycoplasma status was given and ammonia production was not measured according to proliferating cell numbers.
The results of our study shown here are as yet the first reported finding of excess ammonia production in vitro by myeloma cells. These results were not perturbed by infected mycoplasma, because all the cell lines used were treated with MRA before application to this study. All six myeloma cell lines used showed more excess ammonia production than the other hematological cell lines, or even than a hepatocellular carcinoma cell line, HepG2. These results confirm that myeloma cells produce ammonia by themselves and that the clinical manifestation of hyperammonemia in cases with myeloma is due to the myeloma itself. Unfortunately, examination of the RNA expression levels for the genes of the enzymes related to ammonia metabolism failed to detect any differences between the myeloma cell lines and the other lines studied. Therefore, the mechanisms involved in ammonia overproduction in myeloma cells still remain unclear. There are several possibilities to be considered including the possibility that the excess ammonia production just accompanies excess protein synthesis in myeloma cells, such as in the synthesis of immunoglobulins, or certain cytokines involved in myeloma biology, such as Il-6 18, 20 or IL-1␤, [65] [66] [67] which induce excess ammonia biosynthesis. In addition, mutations in the genes of the enzymes related to ammonia synthesis [32] [33] [34] which are known in inherited hyperammonemia in childhood may occur in myeloma. [68] [69] [70] Fifty-two patients with myeloma who died were screened in Division of Hematology, Department of Internal Medicine, Kawasaki Medical School during the past 20 years for the presence of hyperammonemia. In contrast with hyperamylasemia, which was found in nine out of 49 (22.0%) examined cases, in 12 out of 20 (60.0%) cases where serum ammonia concentrations were measured, a concentration beyond the upper limits of the normal range was found. Although, unfortunately, we have no data on serum amino acid distributions and cardiac output, or the detailed status of hepatic function tests for these cases, it may be noteworthy that more than half of these myeloma cases showed hyperammonemia during their clinical courses. With our in vitro results and clinical examinations, we suggest that hyperammonemia produced by myeloma cells may be a common clinical manifestation in myeloma. It is important to consider that if the liver functions normally and eliminates toxic substances in vivo, hyperammonemia should not be observed when total myeloma mass in the body is not remarkable. However, once the myeloma mass exceeds the limitations of hepatic detoxification, hyperammonemia should become apparent.
Future experimental and clinical studies are necessary to clarify the mechanisms of excess ammonia production by myeloma cells and to investigate the clinical importance of hyperammonemia in myeloma cases. The results of such investigations may then lead to new strategies for myeloma management and advances in cellular biology.
